Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI ‐Driven Multi‐Omics Into Clinical Pathways
Cancer Medicine · 2026
DOI: 10.1002/cam4.71578 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2026. Verfasst von Fan Bu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Biomarkers, Tumor, Artificial Intelligence. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the 2023 Zhejiang Provincial "Pioneer" and "Pathfinder" R&D Program of the Department of Science and Technology of Zhejiang Province, the Zhejiang Provincial Health Leading Talent Program.
Abstract (Originalsprache)
Background
Lung cancer remains the leading cause of cancer‐related mortality worldwide, highlighting the urgent need for earlier detection within real‐world screening and patient management pathways. Recent advances in multi‐omics technologies have created new opportunities for identifying biomarkers associated with early‐stage lung cancer, particularly in high‐risk populations under clinical surveillance.
Methods
This review systematically evaluates early diagnostic biomarkers across multiple omics layers, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics. It also summarises the application of artificial intelligence (AI), particularly machine learning and deep learning approaches, for integrating and analysing complex multi‐omics datasets to support biomarker discovery and clinical decision‐making.
Results
Multi‐omics strategies are accelerating the identification of molecular signatures relevant to early lung cancer detection. AI‐driven methods enable the extraction of latent patterns from high‐dimensional data, facilitating risk stratification, diagnostic refinement, histological subtyping and treatment planning. The review highlights the clinical utility of these biomarkers and their potential incorporation into screening algorithms, as well as the development of AI‐based clinical decision support systems (CDSS) aligned with real‐world clinical workflows. However, major barriers to clinical translation remain, including multi‐centre data heterogeneity, limited model interpretability affecting clinical trust, regulatory and cost‐effectiveness challenges and insufficient validation in prospective cohorts.
Conclusions
Emerging technologies, such as single‐cell and spatial multi‐omics, along with federated learning frameworks, offer promising solutions to bridge the gap between computational discovery and clinical implementation. The integration of AI and multi‐omics approaches has the potential to advance risk‐adapted and personalised early detection strategies for lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
- The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou, People's Republic of China.
ORCID-Profile: Fan Bu, Zhi-Qiang Ling
Förderung
- the 2023 Zhejiang Provincial "Pioneer" and "Pathfinder" R&D Program of the Department of Science and Technology of Zhejiang Province
- the Zhejiang Provincial Health Leading Talent Program
Zitieren
APA
Bu, F., & Ling, Z. Q. (2026). Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI ‐Driven Multi‐Omics Into Clinical Pathways. Cancer Medicine. https://doi.org/10.1002/cam4.71578
Vancouver
Bu F, Ling ZQ. Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI ‐Driven Multi‐Omics Into Clinical Pathways. Cancer Medicine. 2026. doi:10.1002/cam4.71578
BibTeX
@article{Bu2026,
author = {Bu, Fan and Ling, Zhi-Qiang},
title = {Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI ‐Driven Multi‐Omics Into Clinical Pathways},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71578}
}
EUVIMED